Creo Medical has issued a trading update showing increased licensing and core Creo revenues with steady Consumable sales. Creo, by steadily training more doctors to use its products, expects to see rapidly increasing sales of its dual-energy endoscopy tool: Speedboat. There are now 150 trained doct
18 Jan 2023
Powering towards positive adjusted EBITDA
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Powering towards positive adjusted EBITDA
Creo Medical Group Plc (CREO:LON) | 34.5 0 0.0% | Mkt Cap: 124.7m
- Published:
18 Jan 2023 -
Author:
Robin Davison | John Savin PhD | Daniel Appiah -
Pages:
8
Creo Medical has issued a trading update showing increased licensing and core Creo revenues with steady Consumable sales. Creo, by steadily training more doctors to use its products, expects to see rapidly increasing sales of its dual-energy endoscopy tool: Speedboat. There are now 150 trained doct